Twitter Facebook LinkedIn YouTube

Pascal Biosciences erhält einen Zuschuss vom National Cancer Institute für das Programm zur Akuten Lymphoblastischen Leukämie

Video Platform Video Management Video Solutions Video Player

Pascal Biosciences, ein Biotechnologie-Unternehmen, das innovative Therapien für schwere Krankheiten, einschließlich COVID-19, anvisiert, wurde vom National Cancer Institute der US National Institutes of Health mit einem Stipendium ausgezeichnet. Damit wird die Entwicklung von Pascals Antikörpermedikament gegen akute lymphatolastische Leukämie oder "ALL" finanziert.

Additional Information:

Company: Pascal Biosciences
Website: http://www.PascalBiosciences.com
Stock Symbol: TSXV: PAS
Date Published: Jun 9, 2021
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

Pascal Biosciences, a biotechnology company targeting innovative therapies for serious diseases, including COVID-19, has been awarded a grant from the National Cancer Institute of the US National Institutes of Health.

This two-year grant of US$343,750 will fund development of Pascal's antibody drug for Acute Lymphoblastic Leukemia or “ALL”.

More than 6,000 patients are diagnosed with this type of leukemia in North America each year, with about half being children, making this the most common childhood leukemia.

Pascal's drug will be eligible for orphan drug designation, which can enable financial incentives and a seven year marketing exclusivity.

Although the number of patients with ALL is relatively small, the market potential for Pascal's drug could be significant.

Other cancer products for orphan diseases have proven to be financially successful, selling over $1 billion each year.

The company has filed for patent protection for its ALL treatment.

Here’s Dr. Patrick Gray, Pascal’s CEO, with some comments and insights about today’s news. Welcome Patrick.

Pascal recently appointed Mark van der Horst as President.

As the president of Gale Capital Corporation since 1993, Mark has extensive capital markets experience and has been CEO of two publicly listed companies on the Canadian Securities Exchange.

The shares are currently trading at $0.12 on the TSX Venture Exchange and recently began trading on the OTC markets under the symbol PSCBF.

For more information, please visit the company’s website at www.PascalBiosciences.com, contact Dr. Patrick W. Gray, CEO, at 206-221-3443, or by email at invest@PascalBiosciences.com.

For investor relations, contact Mark van der Horst, President, at 604-760-7604 or by email at mark@GaleCapital.com.

I’m Megan Edwards for Investmentpitch Media